An FDA advisory panel voted 16-9 against revising the label for the pain drug naproxen to suggest it carries lower heart and stroke risks compared with other nonsteroidal anti-inflammatory drugs. Naproxen is marketed under the brand names Naprosyn by Roche Holding and Aleve by Bayer. According to the panel, there is insufficient evidence to support the claim that naproxen carries less cardiovascular risk than other NSAIDs. The ongoing Precision trial, which is comparing the efficacy of naproxen with ibuprofen and Pfizer's Celebrex, may offer more clarity in the future.

Related Summaries